A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)
Status:
Unknown status
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, parallel, placebo-controlled phase II
clinical study. It is planned to recruit 74 patients with acquired thrombotic
thrombocytopenic purpura (TTP). To evaluate the efficacy and safety of Anfibatide as an
adjuvant therapy for plasma exchange in patients with acquired TTP.